Bedford-based company that makes drugs to treat cancer is under scrutiny ... ...Ben Venue Laboratories Inc. announced on Nov. 19 that it had shut down production, a move that exacerbated an already serious shortage of a critical drug to treat ovarian cancer. The company does not know when it will resume production of the drug Doxil, but is working on correcting the problems as quickly as possible, Boehringer Ingelheim Corp. spokesman Jason Kurtz, said Thursday in an email. Boehringer Ingelheim owns Ben Venue. Kurtz said the company was not prepared to address specific questions at this time, but will make...